stocksfeed.ai
← Back to news feed

PFE overview

PFE
Pfizer, Inc.
28.06
USD
-1.11 (-3.81%)since Nov 16, 2026

News about PFE

2 stories shown

PFEpartnership

Pfizer announced an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion to develop in vivo CAR-T cell therapies for autoimmune diseases.

Benzinga
View original
PFEproduct launch

Pfizer is discontinuing the sale of its hormone replacement therapy Premarin in Canada following an internal review.

Benzinga
View original